Filing Flows › Tenaya Therapeutics (TNYA) › Recalls, complaints & regulation
Tenaya Therapeutics (TNYA): clinical trials
Tenaya Therapeutics (TNYA) beyond its filings: 4 active clinical trials.
Tenaya Therapeutics' latest quarter
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Tenaya Therapeutics have?
4 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.